Ceryvyn Therapeutics ASX:CYV -7.69% Cash And Cash Equivalents is A$74.41 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.
Ceryvyn Therapeutics‘s quarterly cash and cash equivalents
declined
from Jun. 2024 (A$259.74 Mil) to Dec. 2024 (A$208.30 Mil) but then
stayed the same
from Dec. 2024 (A$208.30 Mil) to Jun. 2025 (A$74.41 Mil).
Ceryvyn Therapeutics‘s annual cash and cash equivalents
increased
from Jun. 2023 (A$132.89 Mil) to Jun. 2024 (A$259.74 Mil) but then
declined
from Jun. 2024 (A$259.74 Mil) to Jun. 2025 (A$74.41 Mil).
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Depreciation estimates make the calculation of net income susceptible to management’s accounting choices. These choices can be either overly aggressive or overly conservative.
Ceryvyn Therapeutics Cash And Cash Equivalents Related Terms
Cash, Cash Equivalents, Marketable Securities
Ceryvyn Therapeutics Cash And Cash Equivalents Historical Data
The historical data trend for Ceryvyn Therapeutics‘s Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company’s associated stock exchange currency.
Ceryvyn Therapeutics Cash And Cash Equivalents Chart
Ceryvyn Therapeutics Cash And Cash Equivalents Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
What does a Cash And Cash Equivalents of A$74.41 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Cash And Cash Equivalents of A$74.41 Mil as of Jun. 2025. Cash and cash equivalents represents the total cash and other short-term investments on hand. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics’ Cash And Cash Equivalents too high?
Ceryvyn Therapeutics’ current Cash And Cash Equivalents is A$74.41 Mil.
How does Ceryvyn Therapeutics’ Cash And Cash Equivalents compare to VRTX and REGN?
Ceryvyn Therapeutics’ Cash And Cash Equivalents of A$74.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash And Cash Equivalents for a Biotechnology company?
A good Cash And Cash Equivalents depends on the Biotechnology industry context. However, Cash And Cash Equivalents should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash And Cash Equivalents mean?
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Cash And Cash Equivalents of A$74.41 Mil. The current Cash And Cash Equivalents is A$74.41 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash And Cash Equivalents calculated?
Ceryvyn Therapeutics Business Description
Address
C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.